Carregant...
Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
Treprostinil is a potent prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH, World Health Organization Group I). Previously, treprostinil was available only in subcutaneous (SC) or intravenous (IV) formulations. Availability of an inhaled formulation of trep...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Medknow Publications
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3641714/ https://ncbi.nlm.nih.gov/pubmed/23662183 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2045-8932.109926 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|